H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight

Rhea-AI Summary

H. pylori infections market (CPIX) is projected to expand from a USD 270 million market in 2025 at a 9.4% CAGR through 2036 across the 6MM. US holds ~85% of 2025 revenue and ~57 million diagnosed prevalent cases; emerging therapies such as rifasutenizol, linaprazan glurate, and tegoprazan are expected to reshape treatment paradigms with reported Phase III eradication rates >90% for some candidates.

Challenges include a limited pipeline, geographic regulatory gaps, rising antibiotic resistance, and adherence issues with high pill burdens.

Positive

• Market size USD 270M in 2025
• CAGR 9.4% (2026–2036)
• US accounts for 85% of 2025 market revenue
• Rifasutenizol Phase III reported >90% eradication
• NDA for rifasutenizol accepted by China NMPA (Aug 2025)

Negative

• Emerging pipeline is limited
• Vonoprazan not approved in EU4/UK
• Concomitant quadruple therapy raises antimicrobial stewardship concerns
• High pill burden from bismuth regimens may reduce adherence

News Market Reaction – CPIX

-4.09% 2.3x vol

21 alerts

-4.09% Session close to close

-16.7% Trough in 4 hr 47 min

$65.51M Market Cap

2.3x Rel. Volume

In the Mar 5 session, CPIX declined 4.09%, reflecting a moderate negative market reaction. Argus tracked a trough of -16.7% from its starting point during tracking. Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility. Trading volume was elevated at 2.3x the daily average, suggesting increased selling activity.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights a growing H. pylori treatment market, citing a USD 270 million 2025 mar...

Analysis

This announcement highlights a growing H. pylori treatment market, citing a USD 270 million 2025 market in the 6MM and a projected 9.4% CAGR. It underscores rising diagnosed prevalence, high eradication rates for quadruple regimens, and late-stage candidates such as rifasutenizol and linaprazan glurate. For CPIX, Talicia already participates in this space, so investors may watch how market share evolves, how new entrants are positioned, and whether treatment guideline shifts affect branded therapies.

Key Figures

Market CAGR: 9.4% Market Size 2025: USD 270 million Diagnosed cases 6MM: 147 million +5 more

8 metrics

Market CAGR 9.4% H. pylori infections market CAGR during 2022–2036 in 6MM

Market Size 2025 USD 270 million H. pylori infections market size in 6MM in 2025

Diagnosed cases 6MM 147 million Total diagnosed prevalent H. pylori infections in 6MM in 2025

US diagnosed cases 57 million Diagnosed prevalent H. pylori infections in the US, baseline year not specified

US market share 85% US share of H. pylori infection treatment market size in 2025

Efficacy gain with bismuth 30–40% increase Eradication efficacy gain vs resistant H. pylori when adding bismuth

Quadruple therapy efficacy >90% eradication Eradication rates for bismuth-based and concomitant quadruple therapies

Rifasutenizol Phase III efficacy >90% eradication Phase III rifasutenizol eradication rate vs bismuth quadruple therapy

Historical Context

5 past events · Latest: Feb 25 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 25	Talicia promotion launch	Positive	+4.6%	Cumberland began national U.S. sales promotion for Talicia under co-commercialization deal.
Feb 25	Talicia JV launch	Positive	+4.6%	RedHill and Cumberland activated joint U.S. commercialization entity for Talicia with $4M investment.
Feb 24	Earnings date notice	Neutral	+4.6%	Company scheduled release of 2025 annual results and update with investor conference call.
Feb 04	Ifetroban Fast Track	Positive	+4.0%	FDA granted Fast Track for ifetroban in DMD heart disease after encouraging Phase 2 data.
Dec 08	Caldolor J-code pricing	Positive	-9.2%	CMS linked Caldolor’s permanent J-code to a reimbursement price supporting non-opioid use.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent CPIX news has mostly seen positive price alignment, with one notable divergence on favorable reimbursement news.

Recent Company History

Over the past several months, CPIX has announced commercial and regulatory milestones across its portfolio. Talicia’s U.S. promotion launch and joint commercialization structure supported H. pylori positioning, while an FDA Fast Track designation for ifetroban in DMD heart disease strengthened the pipeline. Financial updates highlighted growing revenues and improving profitability. Against this backdrop, today’s industry-wide H. pylori market growth article contrasts with CPIX’s sharp pre-news decline, despite Talicia’s role in this therapeutic area.

Key Terms

rt-pcr, phase iii, p-cab, nda, +4 more

8 terms

rt-pcr medical

"Molecular diagnostic methods, especially RT-PCR, constitute a significant strength..."

RT-PCR is a laboratory test that converts a tiny amount of genetic material from a sample into many copies so specific viral or genetic targets can be detected, like photocopying one page until you have enough to read clearly. For investors, RT-PCR matters because its accuracy, capacity, and regulatory approval drive demand for diagnostic equipment, testing services, and related supply chains, and can influence revenue and market sentiment around healthcare and biotech companies.

phase iii medical

"Phase III trials reported eradication rates >90%, demonstrating superiority..."

A Phase III trial is the late-stage clinical study that tests whether a medical treatment works and is safe in a large group of patients, often comparing it to standard care. Think of it as a final dress rehearsal or full-scale road test before regulators decide on approval; positive or negative results strongly influence a drug maker’s chance to sell the treatment, future revenue, and investment risk.

p-cab medical

"As a prodrug of linaprazan and a member of the PCAB class..."

A P‑CAB is a class of prescription drugs that quickly and strongly reduces stomach acid by blocking the mechanism that produces it, offering an alternative to older acid‑reducing medicines. For investors, P‑CABs matter because they can change patient preferences, market share, and pricing in gastroenterology: faster relief, different side‑effect profiles, patent protection and regulatory approval determine commercial potential much like a new, more efficient appliance can displace an older model.

nda regulatory

"the New Drug Application (NDA) for rifasutenizol capsules to treat H. pylori..."

An NDA, or nondisclosure agreement, is a legal contract that keeps certain information private between parties. It’s like a promise not to share sensitive details, helping protect business ideas, strategies, or data from being leaked or used without permission. For investors, NDAs help ensure that confidential information remains secure, enabling trust and open communication during business discussions.

maa regulatory

"updated its ongoing UK Marketing Authorisation Application (MAA) for TALICIA..."

MAA stands for Marketing Authorization Application, the formal request a drug developer files with regulators (commonly in the European Union) asking for permission to sell a medicine. Think of it like applying for a driver’s license for a product: approval means the company can market and earn revenue from the drug, while rejection or delays affect expected sales, timelines and the company’s valuation—so investors track MAAs as key risk/reward milestones.

nmpa regulatory

"was accepted by China's National Medical Products Administration (NMPA)."

China’s National Medical Products Administration is the government agency that reviews and approves medicines, medical devices and cosmetics, and enforces safety and quality rules. Think of it as a gatekeeper or traffic controller: its approvals and inspections determine whether a product can be sold, how quickly it reaches patients, and what safety or labeling rules apply—factors that directly affect a healthcare company’s sales, costs and regulatory risk for investors.

mhra regulatory

"under the UK Medicines and Healthcare products Regulatory Agency's (MHRA)..."

The MHRA is the United Kingdom’s government agency that checks and approves medicines, medical devices and vaccines before they can be sold, and monitors their safety once on the market. For investors, MHRA decisions act like a building inspector’s sign-off or a traffic controller’s clearance—approval clears the way for sales and revenue, while safety warnings, recalls or delays can slow launches, raise costs or hurt a product’s commercial prospects.

q3 2025 technical

"H. pylori infections treatment market report proffers epidemiological analysis for the study period 2022–2036..."

Q3 2025 denotes the third quarterly reporting period in the year 2025 — a three-month window companies use to measure sales, profit and operational progress (for calendar-year firms this is typically July through September). Investors watch Q3 reports like a short-term report card because they reveal recent performance, trends and any changes to expectations about future results, which can move a stock’s price and influence buy/sell decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

The H. pylori infection market is evolving as treatment strategies shift toward optimized, targeted combination therapies, including triple- and quadruple-drug regimens, bismuth-based therapies, and novel emerging therapies such as Rifasutenizol (TenNor Therapeutics), Linaprazan glurate (Cinclus Pharma), Tegoprazan (RQ-00000004) (RaQualia Pharma/HK inno.N/Sebela Pharmaceuticals), and others, driven by improved eradication rates and safety profiles.

LAS VEGAS, March 4, 2026 /PRNewswire/ -- Recently published H. pylori Infections Market Insights report includes a comprehensive understanding of current treatment practices, H. pylori infections emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), and the United Kingdom]. 

H. pylori Infections Market Summary

• The market size for H. pylori infections was found to be USD 270 million in the 6MM in 2025.
• The United States accounted for the largest H. pylori infection treatment market size in 2025, i.e 85%, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom.
• In the United States, the maximum market share is expected to be captured by Vonoprazan (VOQUEZNA Dual & Triple Pak) in 2036.
• In the 6MM, the total diagnosed prevalent cases of H. pylori infection were around 147 million in 2025 and are projected to grow during the forecast period (2026–2036).
• Leading H. pylori infection companies, such as TenNor Therapeutics, Cinclus Pharma, RaQualia Pharma, HK-inno.N, Braintree (Sebela Pharmaceuticals), and others, are developing new H. pylori infections treatment drugs that can be available in the H. pylori infections market in the coming years. 
• The promising H. pylori infection therapies in clinical trials include Rifasutenizol (TNP-2198), Linaprazan Glurate, Tegoprazan/RQ-00000004, and others.

Discover H. pylori infections market forecast 2036 @ https://www.delveinsight.com/sample-request/helicobacter-pylori-infections-6mm-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr

Key Factors Driving the Growth of the H. pylori Infections Market 

• Rising H. pylori Prevalence: According to DelveInsight's estimates, the total number of diagnosed prevalent cases of H. pylori infection was approximately 57 million in the US. Due to advancements in diagnosis, increased disease awareness, and ongoing public health efforts, this number is projected to increase by 2036.
• Role of RT-PCR in Tailored H. pylori Treatment: Molecular diagnostic methods, especially RT-PCR, constitute a significant strength due to their superior sensitivity, rapid turnaround, and capacity to identify antibiotic resistance, facilitating tailored and more effective H. pylori eradication.
• Impact of Bismuth Addition on Treatment Resistance: Incorporation of bismuth into conventional triple therapy represents a key therapeutic strength, delivering a 30–40% increase in eradication efficacy against clarithromycin- and metronidazole-resistant H. pylori.
• Implications of Adult–Pediatric Differences in H. pylori Guidelines: Given H. pylori's established role in gastric cancer, adult treatment guidelines support widespread eradication to reduce long-term cancer risk. The more cautious pediatric recommendations highlight the need for targeted, age-specific strategies, creating opportunities for tailored prevention and intervention programs.
• Launch of Emerging Therapies: The dynamics of the H. pylori infection market are anticipated to change in the coming years due to the launch of emerging drugs such as Rifasutenizol (TenNor Therapeutics), Linaprazan glurate (Cinclus Pharma), Tegoprazan (RQ-00000004) (RaQualia Pharma/HK inno.N/Sebela Pharmaceuticals), and others.

Aparna Thakur, Assistant Project Manager, Forecasting and Analytics at DelveInsight, said that the regional dynamics show the US leading in market revenue, while European markets exhibit steady growth, reflecting increasing antibiotic resistance awareness and greater adoption of novel regimens such as vonoprazan- and rifabutin-based therapies.

H. pylori Infections Market Analysis

• Bismuth-based and concomitant quadruple therapies are recommended as empiric first-line options, with both four-drug regimens achieving >90% eradication rates in clinical studies.
• Concomitant quadruple therapy exposes patients to an additional, potentially unnecessary antibiotic, raising concerns regarding antimicrobial stewardship.
• Pre-packaged therapies such as VOQUEZNA and the TALICIA combination are preferred due to their ease of use and convenience.
• Traditional regimens containing bismuth and tetracycline require high pill burdens, making patient adherence more challenging, whereas blister-pack formats are increasingly well-received.
• Vonoprazan, long approved and widely used in Japan under the brand TAKECAB, has limited regulatory availability in Western markets, currently available in the US but not approved in the EU4 or the UK.
• Rifabutin-based triple therapy (TALICIA) is FDA-approved in the US but not approved by the EMA, although the UK may become the first European market to authorize a rifabutin-based triple regimen.
• The emerging H. pylori infection pipeline remains limited, with only a few therapies currently in development, including ifasutenizol (TNP-2198; TenNor Therapeutics), Linaprazan glurate (Cinclus Pharma), and Tegoprazan/RQ-00000004 (RaQualia Pharma/HK-inno.N/Braintree)

H. pylori Infections Competitive Landscape

Some of the H. pylori drugs in the pipeline include Rifasutenizol (TenNor Therapeutics), Linaprazan glurate (Cinclus Pharma), Tegoprazan (RQ-00000004) (RaQualia Pharma/HK inno.N/Sebela Pharmaceuticals), and others.

TenNor Therapeutics' Rifasutenizol is an experimental oral antibacterial agent from TenNor Therapeutics that combines rifamycin and nitroimidazole components in one molecule to create a synergistic, multi-target mechanism. It is intended to treat H. pylori and other microaerophilic or anaerobic bacteria, including antibiotic-resistant strains, by addressing current gaps in available therapies.

According to Aparna, Rifasutenizol shows strong efficacy in H. pylori infection, emerging as a potential first-in-class, purpose-designed therapy in a field with little innovation for decades. Phase III trials reported eradication rates >90%, demonstrating superiority or non-inferiority to bismuth-based quadruple therapy, including in antibiotic-resistant strains. Its differentiation lies in a single-molecule dual mechanism combining rifamycin-mediated RNA polymerase inhibition with nitroimidazole-induced DNA damage, providing intrinsic synergy, greater potency, and lower resistance risk without added regimen complexity.

Cinclus Pharma's Linaprazan glurate is an investigational next-generation gastric acid–suppressing drug. As a prodrug of linaprazan and a member of the PCAB class, it is designed to produce quicker and longer-lasting acid suppression than standard proton-pump inhibitors. By reversibly blocking the gastric proton pump, it aims to deliver rapid and sustained 24-hour acid control to improve healing and symptom management in conditions such as moderate to severe erosive GERD, and may also be useful in combination regimens for H. pylori treatment.

RaQualia Pharma/HK inno.N/Sebela Pharmaceuticals' Tegoprazan is a newer potassium-competitive acid blocker (P-CAB) used to inhibit gastric acid secretion. Unlike traditional PPIs, long relied upon for GERD, P-CABs act faster and maintain acid suppression more consistently, offering a next-generation approach to managing acid-related disorders.

The anticipated launch of these emerging therapies are poised to transform the H. pylori infections market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the H. pylori infections market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about emerging H. pylori therapies pipeline @ H. pylori Infections Drugs 

Recent Developments in the H. pylori Infections Market

• In January 2026, RedHill Biopharma updated its ongoing UK Marketing Authorisation Application (MAA) for TALICIA for the treatment of H. pylori infection, under the UK Medicines and Healthcare products Regulatory Agency's (MHRA) International Recognition Procedure, a fast‑track process that uses the US FDA approval as a reference.
• In November 2025, Cinclus Pharma reported that it plans to begin clinical studies on H. pylori this year, with the expected results available in 2027. It aims to submit applications for regulatory approval to the FDA and EMA in 2027, to obtain approval by 2028 or 2029.
• In August 2025, the New Drug Application (NDA) for rifasutenizol capsules to treat H. pylori infection was accepted by China's National Medical Products Administration (NMPA).
• In June 2025, Cinclus Pharma announced that it had been granted a waiver from the requirement to conduct pediatric studies with linaprazan glurate for the treatment of H. pylori infection by both the US FDA and the EMA.
• In May 2025, TenNor Therapeutics presented the results of the Phase III (EVEREST-HP) trial evaluating rifasutenizol as a first-line treatment in patients with H. pylori infection at Digestive Disease Week (DDW) 2025.

What are H. pylori Infections?

Helicobacter pylori (H. pylori) infections occur when a type of bacteria called H. pylori colonizes the stomach lining. This bacterium can weaken the protective mucus layer of the stomach and small intestine, allowing stomach acid to cause irritation. Many people with H. pylori don't experience symptoms, but when symptoms do occur, they may include stomach pain, nausea, bloating, or frequent burping. Over time, the infection can lead to conditions such as gastritis, peptic ulcers, and, in rare cases, stomach cancer. H. pylori is usually spread through contaminated food, water, or close contact, and it can be diagnosed with breath, blood, stool, or endoscopy tests. Fortunately, it is treatable with a combination of antibiotics and acid-reducing medications.

H. pylori Infections Epidemiology Segmentation

The H. pylori infections epidemiology section provides insights into the historical and current H. pylori infections patient pool and forecasted trends for the leading markets. The total number of diagnosed prevalent cases of H. pylori infection was approximately 57 million in the US. Due to advancements in diagnosis, increased disease awareness, and ongoing public health efforts, this number is projected to increase by 2036.

The H. pylori infections treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Total Diagnosed Prevalent Cases of H. pylori Infection
• Age-specific Diagnosed Prevalent Cases of H. pylori Infection 
• Gender-specific Diagnosed Prevalent Cases of H. pylori Infection
• Total Treated Cases of H. pylori Infection

H. pylori Infections Market Report Metrics	Details
Study Period	2022–2036
Coverage	6MM [The United States, the EU4 (Germany, France, Italy, and Spain), and the United Kingdom].
H. pylori Infections Market CAGR	9.4 %
H. pylori Infections Market Size in 2025	USD 270 Million
Key H. pylori Infections Companies	TenNor Therapeutics, Cinclus Pharma (STO: CINPHA), RaQualia Pharma (TYO: 4579), HK-inno.N (KOSDAQ: 195940), Braintree (Sebela Pharmaceuticals), RedHill BioPharma (NASDAQ: RDHL), Cumberland Pharmaceuticals (NASDAQ: CPIX), Phathom Pharmaceuticals (NASDAQ: PHAT), and others
Key H. pylori Infections Therapies	Rifasutenizol (TNP-2198), Linaprazan Glurate, Tegoprazan/RQ-00000004, TALICIA, VOQUEZN TRIPLE, VOQUEZNA DUAL, and others

Scope of the H. pylori Infections Market Report

• Therapeutic Assessment: H. pylori Infections current marketed and emerging therapies
• H. pylori Infections Market Dynamics: Key Market Forecast Assumptions of Emerging H. pylori Infections Drugs and Market Outlook
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, H. pylori Infections Market Access and Reimbursement

Download the report to understand H. pylori diagnostics market trends @ H. pylori Infections Market Analysis

Table of Contents

1	H. pylori Infections Market Key Insights
2	H. pylori Infections Market Report Introduction
3	Executive Summary
4	Key Events
5	Epidemiology and Market Forecast Methodology
6	H. pylori Infection Market Overview at a Glance
6.1	Clinical Landscape Analysis (By Phase, Molecule Type, and RoA)
6.2	Market Share (%) Distribution of H. pylori Infection By Therapies in the 6MM, in 2025
6.3	Market Share (%) Distribution of H. pylori Infection By Therapies in the 6MM, in 2036
7	Disease Background and Overview
7.1	Introduction
7.2	Causes and Risk Factors
7.3	Physiopathology
7.4	Signs and Symptoms
7.5	Diagnosis
8	Treatment
8.1	Treatment Algorithm
8.2	Treatment Guidelines
9	Epidemiology and Patient Population
9.1	Key Findings
9.2	Assumptions and Rationale
9.3	Diagnosed Prevalent Cases of H. pylori Infection in the 6MM
9.4	The United States
9.4.1	Total Diagnosed Prevalent Cases of H. pylori Infection in the United States
9.4.2	Age-specific Diagnosed Prevalent Cases of H. pylori Infection in the United States
9.4.3	Gender-specific Diagnosed Prevalent Cases of H. pylori Infection in the United States
9.5	EU4 and the UK
10	H. pylori Infections Patient Journey
11	Marketed H. pylori Infections Therapies
11.1	Key Cross Competition
11.2	Omeprazole Magnesium, Amoxicillin, and Rifabutin (TALICIA): RedHill BioPharma/Cumberland Pharmaceuticals
11.2.1	Drug Description
11.2.2	Regulatory Milestones
11.2.3	Other Developmental Activities
11.2.4	Summary of Pivotal Trials
11.2.5	Analyst Views
11.3	Vonoprazan, Amoxicillin, Clarithromycin (VOQUEZNA TRIPLE) and Vonoprazan, Amoxicillin (VOQUEZNA DUAL) PAKs: Phathom Pharmaceuticals
11.4	Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Hydrochloride (PYLERA): Juvisé Pharmaceuticals/AbbVie
12	Emerging H. pylori Infections Drugs
12.1	Key Cross Competition
12.2	Rifasutenizol (TNP-2198): TenNor Therapeutics
12.2.1	Drug Description
12.2.2	Other Developmental Activities
12.2.3	Clinical Development
12.2.3.1	Clinical Trials Information
12.2.4	Analyst Views
13	H. pylori Infection Market: 6MM Analysis
13.1	Key Findings
13.2	H. pylori Infections Market Outlook
13.3	Key H. pylori Infections Market Forecast Assumptions
13.4	Conjoint Analysis
13.5	Total Market Size of H. pylori Infection in the 6MM
13.6	Total Market Size of H. pylori Infection by Therapies in the 6MM
13.7	The United States H. pylori Infections Market
13.7.1	Total Market Size of H. pylori Infection in the United States
13.7.2	Total Market Size of H. pylori Infection by Therapies in the United States
13.8	EU4 and the UK H. pylori Infections Market
13.8.1	Total Market Size of H. pylori Infection in EU4 and the UK
13.8.2	Total Market Size of H. pylori Infection by Therapies in EU4 and the UK
14	H. pylori Infections Market Unmet Needs
15	H. pylori Infections Market SWOT Analysis
16	KOL Views on H. pylori Infections
17	H. pylori Infections Market Access and Reimbursement
17.1	The United States
17.2	EU4 and the UK
17.3	Summary and comparison of Market Access and Pricing Policy Developments in 2025
17.4	Market Access and Reimbursement of H. pylori Infection Therapies
18	Bibliography
19	H. pylori Infections Market Report Methodology

Related Reports

H. pylori Infections Clinical Trial Analysis

H. pylori Infections Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key H. pylori infections companies, including TenNor Therapeutics (Suzhou) Limited, Servatus Biopharmaceuticals, TenNor Therapeutics Inc., and others.

Bacterial Vaginosis Market

Bacterial Vaginosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bacterial vaginosis companies including Aurobindo Pharma, AbbVie Inc., Bayer AG, Melinta Therapeutics, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Lupin, Osel, Darebioscience, Organon, Gedea Biotech, Pfizer Inc., Mission Pharmacal Company, Siolta Therapeutics, Mylan N.V., Novartis AG, Hikma Pharmaceuticals plc, and others.

Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Market

Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HABP/VABP companies including Basilea, Merck, Shionogi, Pfizer, Aridis Pharmaceuticals, Polyphor, Aerucin, Motif Bio, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg 

 

View original content:https://www.prnewswire.com/news-releases/h-pylori-infections-market-in-the-6mm-to-observe-stupendous-growth-at-a-cagr-of-9-5-during-the-forecast-period-20262036--delveinsight-302702268.html

SOURCE DelveInsight Business Research, LLP

FAQ

What is the 2025 H. pylori infections market size and CAGR for the 6MM (CPIX)?

The H. pylori infections market was USD 270 million in 2025 with a 9.4% CAGR. According to DelveInsight, this forecast covers the 6MM (US, EU4, UK) and reflects projected growth through 2036 driven by emerging therapies and diagnostics.

How large is the diagnosed H. pylori patient pool in the US and 6MM for 2025 (CPIX)?

The US had approximately 57 million diagnosed prevalent cases in 2025, with the 6MM totaling around 147 million. According to DelveInsight, improved diagnosis and awareness are expected to increase these numbers by 2036.

What impact could rifasutenizol have on the H. pylori market and CPIX investors?

Rifasutenizol reported >90% eradication rates in Phase III, suggesting strong clinical differentiation. According to DelveInsight, successful launches could shift market share toward purpose‑designed antibiotics and change standard-of-care regimens over the next decade.

Why does DelveInsight say the US leads H. pylori market revenue in 2025 (CPIX)?

The US represented about 85% of 2025 market revenue due to higher adoption of new therapies and reimbursement dynamics. According to DelveInsight, regional uptake and diagnostic penetration explain the US revenue concentration.

What regulatory gaps and risks should investors watch for in H. pylori therapies (CPIX)?

Key risks include limited approvals in Europe (e.g., vonoprazan not authorized in EU4/UK) and variable EMA/MHRA decisions. According to DelveInsight, regulatory timing differences may delay revenue realization across major markets.